Journals shouldn't accept ads: article

Share this article:
An article in PLoS Medicine called for medical journals to reject ads from drug companies, saying they compromise the objectivity of journals.

The article, co-authored by Georgetown University Medical Center professor and HRT critic Adriane Fugh-Berman, examined ads in nine medical journals, concluding they were “unreliable sources of information, since they ‘educate' physicians to prescribe the newest, most expensive drugs (which may not be superior to existing, less expensive alternatives).” Publishers could replace the lost income with consumer products advertising, the authors said. 

PLoS Medicine, a nonprofit, does not accept drug ads.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...